Chromatide, a provider of innovative polymer technologies designed to improve and enhance pharmaceutical and chemical production and processes, and Separation Product´s Kromasil®, a brand of Akzo Nobel, today announced that they have set up a research collaboration. The aim of the collaboration is to develop and bring to market improved silica-based high performance liquid chromatography media, with particular emphasis in the area of chiral purification.

This collaboration combines Chromatide’s unique skills and experience in the area of polymer synthesis for use in a range of applications including synthesis and chromatography, with Akzo Nobel expertise in the business of developing, producing and marketing materials for use in separation techniques.

Commenting on the announcement, Dr Don Wellings, Chromatide’s CSO, said, “We are delighted to be working alongside Akzo Nobel, a company with such a strong, global reputation in the specialty chemicals market”. He added, “This collaboration allows us to rapidly apply our expertise in developing polymers for use in chromatographic techniques with the knowledge that products resulting from this collaboration will be marketed very quickly via Akzo Nobel´s well established routes”.

About Chromatide Limited

Chromatide was founded in 2005 by Dr. Don Wellings, former Technology Manager at Polymer Laboratories, and Dr. Saeed Gulzar, formerly Custom Peptide Synthesis Manager at Avecia/Zeneca. The IP-driven company is a provider of innovation polymer technologies, to improve & enhance pharmaceutical production and chemical production. It specialises in novel biosynthesis and purification technologies designed to facilitate, and reduce costs, of the processes involved in production of biomolecules in the biotechnology and pharmaceutical industries. The founders hold a range of key patents in the field of novel polymers for use in research and development, as well as process-scale, in a range of applications including biomolecule purification and synthesis. The Chromatide team is extremely experienced in successfully developing and completing high quality research, development and processes to continually improve the production of biomolecules in drug discovery, development and process-scale programmes and is building an exciting patent portfolio. The Company is also able offer these skills in research services as a flexible resource and specialise in synthesis and purification of complex molecules and large scale projects with services including:

·Purification of peptides, proteins and small molecules

·Synthesis of complex peptides

-Large scale DNA , peptide and polymer synthesis

About Akzo Nobel

Akzo Nobel is a Global Fortune 500 company and is listed on both the Euronext Amsterdam and NASDAQ stock exchanges. It is also listed on the Dow Jones Sustainability Indexes. Based in the Netherlands, we are a multi-cultural organization, serving customers throughout the world with human and animal healthcare products, coatings and chemicals. We employ around 61,500 people and conduct our activities in four segments − human and animal health, coatings and chemicals −subdivided into 13 business units, with operating subsidiaries in more than 80 countries.

www.akzonobel.com